Talazoparib improves PFS over chemotherapy for patients with BRCA mutations

Dec 13th, 2017 - The PARP inhibitor talazoparib improved PFS over investigator’s choice chemotherapy among patients with advanced breast cancer and a BRCA germline mutation, according to results of the phase 3 EMBRACA study presented at the San Antonio Breast Cancer Symposium.

Temporary ovarian suppression preserves fertility during chemotherapy

Dec 6th, 2017 - Women treated with gonadotropin-releasing hormone agonists during treatment with chemotherapy for premenopausal early breast cancer experienced a significant reduction in the risk for chemotherapy-induced premature ovarian insufficiency, according to data from a systemic review and meta-analysis presented at the San Antonio Breast Cancer Symposium.

Abstract P5-22-04: Efficacy of thoracic paravertebral block for reducing acute post-mastectomy pain

Dec 18th, 2018 - Background: Mastectomy is associated with acute and chronic postoperative pain. This study investigated the efficacy of thoracic paravertebral block (TPB) compared to local anesthetic of surgical wound (LASW) in breast cancer patients undergoing mastectomy. Methods: This phase 3, randomized controlled, single blind, parallel arms and superiority clinical trial aimed to evaluate the efficacy of ...

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers

Dec 7th, 2017 - Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.

Trastuzumab Disappoints in HER2-low Patient Cohort

Dec 5th, 2017 - A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

Abstract P6-13-04: IMPACt trial: MammaPrint and BluePrint molecular subtyping guide treatment decisions in breast cancer

Sep 15th, 2018 - Background: IMPACt is a prospective, case-only study to measure the effect of MammaPrint (MP) and BluePrint (BP) on treatment decisions in breast cancer patients. Here, we report the results of the primary objective in women aged ≥18 years with histologically proven invasive stage I-II, hormone receptor (HR) positive, and HER2-negative breast cancer. Methods: The study included 369 women from 1...

Abstract P5-22-10: Intraoperative ultrasound guided surgery after neoadjuvant treatment in breast cancer improves patient´s quality of life

Dec 20th, 2018 - Background: Intraoperative ultrasound guided surgery (IOUS) has shown not only to improve surgical outcomes by achieving higher rates of negative margins and reducing the need for re-excisions, but also showing better cosmetic results and patient's satisfaction in the adjuvant setting. After neoadjuvant treatments (NAT) we have shown that IOUS lowers the volume of resection in patients with pat...

Wider margins may reduce recurrence risk in early breast cancer

Jan 1st, 2018 - A margin width beyond ‘no tumor on ink’ may reduce local recurrence in certain subsets of patients undergoing breast-conserving treatment for early-stage breast cancer, according to findings from a meta-analysis.

Abstract P6-13-03: Breast cancer-specific mortality (BCSM) in patients with node-positive (N+) breast cancer (BC) treated based on the 21-gene assay in clinical practice

Sep 17th, 2018 - Introduction: The Recurrence Score® (RS) assay was shown in SWOG 8814 to predict chemotherapy (CT) benefit for patients (pts) with N+ BC and RS ≥31 but not RS <18. As we await the randomized RxPONDER results for RS 0-25, we characterized BCSM for RS groups (cutoffs of 11, 18, 25, and 31) in the large population-based SEER study of pts treated based on RS results. Methods: RS results were provid...

Abstract P5-22-19: Nipple sparing mastectomy in unselect patients: Experience of an academic center in the south of Brazil

Dec 21st, 2018 - INTRODUCTION: Nipple sparing mastectomy (NSM) consists in the complete excision of the breast gland, mantaining the subcutaneous tissue, skin and nipple-areola complex (NAC). Recently, the NSM was developed as a therapeutic option not just for the patients that need risk-reducing surgery, but also for patients that have tumors not involving the NAC. OBJECTIVES: Evaluate the overall survival, di...

Abstract P1-01-01: The blood-Tumor barrier as a therapeutic target to improve therapy of brain metastases of breast cancer

Feb 14th, 2018 - Objectives: Brain metastases of breast cancer demonstrate low and heterogeneous levels of permeability to drugs in mouse models and human craniotomies. The Blood-Brain Barrier (BBB), the protective lining of CNS blood vessels, impedes drug entry into the normal brain. When a metastasis forms, the BBB is locally altered to a poorly characterized Blood-Tumor Barrier (BTB). Quantitative experiment...

Abstract P1-15-03: Management and outcomes of metaplastic breast cancer

Sep 21st, 2018 - Purpose/Objectives: Metaplastic breast cancer (MBC) is a rare malignancy composed of both epithelial and mesenchymal components that accounts for less than 1% of primary breast carcinomas. Knowledge of effective management of the disease remains limited. We retrospectively evaluated the treatment and outcomes of patients with MBC from three academic hospitals. Materials/Methods: Patients diagno...

Abstract GS5-04: Prediction of occult invasive disease in ductal carcinoma in situ using deep learning features

Feb 27th, 2018 - Background: Deep learning, especially deep convolutional neural network (CNN), has emerged as a promising approach for many image recognition or classification tasks, demonstrating human or even superhuman performance. Used as feature extractor, some pre-trained CNN models can match or surpass the performance of domain-specific, “handcrafted” features. In this study, we aim to determine whether...

Abstract P5-22-12: Oncological safety of nipple-areola sparing mastectomy in comparison with skin sparing and total mastectomy: Results from a NCI-designated comprehensive cancer center

Dec 26th, 2018 - Nipple-areola sparing mastectomy (NSM) may be offered to some women with breast cancer as an alternative to skin sparing (SSM) or total mastectomy (TM) with excellent cosmetic results and acceptable recurrence risk. The aim of this study is to determine the local/regional recurrence rate of NSM in comparison to SSM and TM at our institution and to determine the factors that may be associated wi...

Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to che...

Mar 7th, 2018 - Purpose Dual HER2 targeting increases pathologic complete response (pCR) rate to neoadjuvant therapy and improves outcomes in both early and metastatic HER2-positive disease. CALGB 40601 is a randomized phase III trial examining the impact of dual HER2 blockade consisting of trastuzumab (H) and lapatinib (L) added to paclitaxel (T) on pCR, considering tumor and microenvironment molecular featur...

Abstract P3-14-03: PRESAGE : Prospective multicenter feasibility study of fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: Preliminary results

Dec 28th, 2018 - Background: Breast cancer is the most frequent form of cancer for young women. For these patients, breast cancer is generally more aggressive and chemotherapy is more often needed. Chemotherapy is commonly associated with amenorrhea and a decrease of ovarian reserve depending on the patient's age, agents and dose. There are no guidelines to prevent subfertility for young women on cytotoxic trea...

Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial

Mar 6th, 2018 - Background In the NeoALTTO trial, the combination of trastuzumab and lapatinib for the neoadjuvant treatment of HER2 positive early breast cancer patients (pts) nearly doubled the rate of pathological complete response (pCR) compared with either anti-HER2 treatment alone. In the same trial, pCR was shown to be a surrogate for long-term outcome. Expression of ERBB2, ESR1 and immune signatures we...

Abstract P3-14-02: Incidence of venous thromboembolism in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors: A systematic review and met...

Dec 29th, 2018 - Background: The cyclin dependent kinases (CDK) along with their partners, the cyclins, have a crucial role in regulation of the cell cycle. Several CDK-targeted agents have been employed in hormone receptor positive metastatic breast cancer (MBC) with noteworthy safety concerns. Nevertheless, the impact of this agent on risk of venous thromboembolism (VTE) remains uncertain. We performed a syst...

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

Mar 10th, 2018 - Background: Pathological complete response (pCR) is accepted by FDA as a surrogate endpoint for accelerated approval of targeted agents in combination with chemotherapy based on better long-term outcomes compared to residual disease (Cortazar 2014). Methods: The multi-center, adaptively-randomized I-SPY2 platform trial uses pCR as the primary endpoint to identify investigational agents that wil...

Abstract P3-14-09: Low rates of chronic breast cancer related lymphedema (BCRL) in a cohort of high-Risk patients undergoing prospective surveillance with bioimpedance spectroscopy (BIS)

Dec 30th, 2018 - Background: We report outcomes using prospective BIS surveillance in a high-risk cohort of patients who all underwent axillary lymph node dissection (ALND). Methods: From 8/2010 through 12/2016, 206 consecutive patients were evaluated with BIS as part of a prospective surveillance program. 30 underwent ALND and constitute the study population. The program included pre-operative BIS measurement ...